crisaborole

Ligand id: 9151

Name: crisaborole

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 62.48
Molecular weight 251.08
XLogP 2.68
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Crisaborole (with research code AN2728) has completed Phase 3 clinical trials as a monotherapy for atopic dermatitis (NCT02118792 and NCT02118766) and has received FDA approval for treatment of mild-to-moderate atopic dermatitis in December 2016.
Mechanism Of Action and Pharmacodynamic Effects
Crisaborole-induced inhibition of PDE4B seems to reduce secretion of pro-inflammatory mediators including tumor necrosis factor alpha (TNFα), interleukin-12 (IL-12), IL-23 and other cytokines [2], to reduce inflammation.